Knowledge about peptides

Basics, practice and background. Clearly explained, without promises.

Semaglutide gave old mice 92 extra days: what the Nature study shows, and what it does not

Research·September 2026·10 min

Semaglutide gave old mice 92 extra days: what the Nature study shows, and what it does not

Continue reading

Nisotirostide (LY3457263): the PYY drug that only exists as a stack — and what the data actually shows

Research·12 min

Nisotirostide (LY3457263): the PYY drug that only exists as a stack — and what the data actually shows

70 months in prison for faked certificates of analysis — the Paradigm Peptides case

70 months in prison for faked certificates of analysis — the Paradigm Peptides case

Enicepatide (Roche's CT-388): what it is, and how it compares to semaglutide, tirzepatide, retatrutide and the amylins

Research·11 min

Enicepatide (Roche's CT-388): what it is, and how it compares to semaglutide, tirzepatide, retatrutide and the amylins

The FDA panel voted yes on BPC-157 and TB-500 — here is what that does and does not change

Regulation·9 min

The FDA panel voted yes on BPC-157 and TB-500 — here is what that does and does not change

Retatrutide TRIUMPH-2 and TRIUMPH-3: the phase-3 results in diabetes and heart disease

Research·6 min

Retatrutide TRIUMPH-2 and TRIUMPH-3: the phase-3 results in diabetes and heart disease

The July 2026 FDA hearing on BPC-157, TB-500 and five more peptides

Regulation·6 min

The July 2026 FDA hearing on BPC-157, TB-500 and five more peptides

GLP-1 dosing errors: why poison-control calls are surging

GLP-1 dosing errors: why poison-control calls are surging

Retatrutide TRIUMPH-1: the phase-3 numbers, and the asterisk

Research·7 min

Retatrutide TRIUMPH-1: the phase-3 numbers, and the asterisk

Retatrutide liver damage: a fact-check

Fact-check·20 min

Retatrutide liver damage: a fact-check

BPC-157 and TB-500: what they are, and their status

Compounds·3 min read

BPC-157 and TB-500: what they are, and their status